A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2001
11/07/2001	EP1150660A1 Pharmaceutical effervescent formulation containing metamizol
11/07/2001	EP1150658A2 Method for controlling liposome size
11/07/2001	EP1150657A1 SPRAY CONTAINING UBIQUINONE Qn
11/07/2001	EP0970043B1 Compounds consisting in particular of effectors of the central nervous system receptors sensitive to excitatory amino acids, preparation and biological applications
11/07/2001	EP0900082B1 Use of pyridyl- and pyrimidyl-piperazines for the manufacture of a medicament for the treatment of substance abuse disorders
11/07/2001	EP0882051B1 Thiophenopyrimidines
11/07/2001	EP0861235B1 Substituted benzylaminopiperidine compounds
11/07/2001	EP0843679B1 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
11/07/2001	EP0783693B1 In vitro models of cns function and dysfunction
11/07/2001	EP0777478B1 Inhibitors of rotamase enzyme activity
11/07/2001	EP0758452B1 Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
11/07/2001	EP0714296B1 Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity
11/07/2001	EP0655996B1 Substituted benzylamino nitrogen containing non-aromatic heterocycles
11/07/2001	EP0546108B1 Pro-drugs for cck antagonists
11/07/2001	CN1321159A Benzothieno [3,2-c]pyridines as alpha 2-antagonists
11/07/2001	CN1321158A Tricyclic delta 3-piperidines as pharmaceuticals
11/07/2001	CN1321155A Process for preparation of non-crystalline anhydrate form of paroxetine hydrochloride
11/07/2001	CN1321087A MGluR 5 antagonists for treatment of pain and anxiety
11/07/2001	CN1321086A Mucosal originated drug delivery system and animal applications
11/07/2001	CN1321084A Pharmaceutical compositions comprising ibuprofen and domperidone
11/07/2001	CN1321083A Method for making coated gabapentine or pregabaline particles
11/07/2001	CN1321080A Fast dissolving orally consumable films
11/07/2001	CN1320601A 6-amino or 6-hydrazino-sulfonyl-3-quinolyl phosphonic acid compound, preparing process thereof and pharmaceutical composition contg. same
11/07/2001	CN1320453A Capsule for treating headache and heimcrania
11/07/2001	CN1320440A Medicine containing active components of Rhodiola crennulata root and preparing process thereof
11/07/2001	CN1320426A Compound for treatment of female sexual dysfuction
11/07/2001	CN1074414C indolylalkyl derivs. of benzodioxanmethylamine as 5-HT1A receptor ligands
11/07/2001	CN1074290C Medicine for treating facial paralysis and its preparing method
11/07/2001	CN1074288C Preparation for stopping smoking and its preparing method
11/07/2001	CN1074287C Medicine for treatment of neurasthenia and its preparation process
11/06/2001	US6313312 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
11/06/2001	US6313311 Imidazole derivatives having affinity for alpha2 receptors
11/06/2001	US6313302 Opioid kappa receptor antagonists; side effect reduction; analgesics, antiinflammatory agents, anesthetics, and neuroprotectants
11/06/2001	US6313298 Spiro-indolines as Y5 receptor antagonists
11/06/2001	US6313290 Azolobenzazepine derivatives and compositions and method of use thereof
11/06/2001	US6313270 DbpB
11/06/2001	US6313175 For therapy of obesity; for quantitating the binding of serotonin or a serotonin ligand
11/06/2001	US6313172 Administering hydroxyethylthiourea derivative for therapy of pain in mammal
11/06/2001	US6313160 Substituted heterocyclic compounds, method for preparing and compositions containing same
11/06/2001	US6313156 Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
11/06/2001	US6313148 For therapy of pain pain associated with joint conditions such as rheumatoid arthritis and osteoarthritis, postoperative pain, post-partum pain, the pain associated with dental conditions such as dental caries and gingivitis
11/06/2001	US6313141 2-aminoalkylaminoquinolines as dopamine D4 ligands
11/06/2001	US6313139 Administering benzylamine derivative for therapy of psychiatric disorder in mammals
11/06/2001	US6313125 Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors
11/06/2001	US6313118 Hydroxytryptamine receptor antagonists
11/06/2001	US6313117 Succinate derivative compounds useful as cysteine protease inhibitors
11/06/2001	US6313116 Phosphodiesterase inhibitors
11/06/2001	US6313115 Alleviate impairment of memory, or other cognitive functions caused by hypoglutamatergic condition or by deficiency in number or strength of excitatory synapses or in number of ampa receptors
11/06/2001	US6313112 Activating neuronal potassium adenosine triphosphate channels with diazoxide
11/06/2001	US6313107 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
11/06/2001	US6313106 Phospholipid derivatives of valproic acid and mixtures thereof
11/06/2001	US6313098 Treating affective disorder characterized by alterations in psychometric variables as sadness, carbohydrate craving or social withdrawal by administering leptin, leptin analog, leptin fragment, leptin fusion protein or leptin
11/06/2001	US6312716 Patch and method for transdermal delivery of bupropion base
11/06/2001	US6312708 Botulinum toxin implant
11/06/2001	US6312703 Drugs or cosmetics, liquid crystal solids and lecithin
11/06/2001	US6312686 Modulating the permeability of a physiological barrier with an agent that modulates tyrosine phosphorylation
11/06/2001	CA2250251C Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
11/03/2001	CA2345760A1 Pharmaceutical uses for fluoroalkoxybenzylamino and alkoxybenzylamino derivatives of nitrogen containing heterocycles
11/01/2001	WO2001081590A2 Protein phosphatases
11/01/2001	WO2001081585A2 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	WO2001081576A2 Novel g protein-coupled receptor con-218
11/01/2001	WO2001081573A1 Edg8 receptor, its preparation and use
11/01/2001	WO2001081562A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
11/01/2001	WO2001081540A2 Growth factor which acts through erb b-4 rtk
11/01/2001	WO2001081413A2 Isolated human transporter proteins, nucleic acids and uses thereof
11/01/2001	WO2001081363A1 Novel compounds
11/01/2001	WO2001081348A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
11/01/2001	WO2001081347A2 Diazabicyclic central nervous system active agents
11/01/2001	WO2001081346A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta
11/01/2001	WO2001081344A1 Salts of bicyclic, n-acylated imidazo-3-amines and imidazo-5-amines
11/01/2001	WO2001081334A2 Cyclic amidine compounds and their use as alpha4beta2 nicotinic acetylcholine receptor ligands
11/01/2001	WO2001081326A1 Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholine receptors activators
11/01/2001	WO2001081323A1 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments
11/01/2001	WO2001081319A2 Ultrashort acting hypnotic barbiturates
11/01/2001	WO2001081312A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
11/01/2001	WO2001081311A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
11/01/2001	WO2001081310A1 1-aroyl-piperidinyl benzamidines
11/01/2001	WO2001081309A2 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
11/01/2001	WO2001081303A1 Pyrrolidine and piperidine derivatives and their use for the treament of neurodegenerative disorders
11/01/2001	WO2001081298A2 Cyclic carboxylic acids as integrin antagonists
11/01/2001	WO2001081296A1 Choline derivatives for the treatment of alzheimer's disease
11/01/2001	WO2001081295A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists
11/01/2001	WO2001080937A1 Drug delivery device for insertion in the vagina, rectum or nasal cavity
11/01/2001	WO2001080875A1 A memory enhancing protein
11/01/2001	WO2001080857A1 Zolpidem hemitartrate
11/01/2001	WO2001080845A2 (2-aminoethyl) oxime derivatives for the treatment of depression
11/01/2001	WO2001080822A2 Effervescent granules and methods for their preparation
11/01/2001	WO2001080796A1 Minimizing adverse experience associated with oxybutynin therapy
11/01/2001	WO2001080619A2 Pharmaceutical composition containing citalopram
11/01/2001	WO2001060381B1 Nucleoside analogs with carboxamidine-modified bicyclic base
11/01/2001	WO2001044239A3 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
11/01/2001	WO2001042306A3 Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
11/01/2001	WO2001041762A3 Valdecoxib compositions
11/01/2001	WO2001041761A3 Valdecoxib compositions
11/01/2001	WO2001038311A3 Pyrimidine derivatives as selective inhibitors of cox-2
11/01/2001	WO2001036641A3 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
11/01/2001	WO2001034640A3 Peptide (virip) which inhibits a circulating virus in humans and the use thereof
11/01/2001	WO2001032866A3 Hybrid adaptor receptors
11/01/2001	WO2001029084A3 Novel human proteins and polynucleotides encoding the same
11/01/2001	WO2001029049A3 Imidazole derivatives as phosphodiesterase vii inhibitors

1 ... 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 ... 1833